Enter a phrase above to search files and articles within the site.

Typically materials that are more than 5 years old will be archived
Displaying 1 - 25 of 343 results

Atopic Dermatitis

https://www.niams.nih.gov/health-topics/atopic-dermatitis

What is atopic dermatitis? Atopic dermatitis, often called eczema, is a chronic (long-lasting) disease that causes the skin to become inflamed and irritated, making it extremely itchy. Scratching leads to: Redness. Swelling. Cracking. “Weeping” clear fluid. Crusting. Scaling. In most cases, there are times when the disease is worse, called flares, followed by times when the skin improves or clears up entirely, called remissions. Atopic dermatitis is a common condition, and anyone can get the disease. However, it usually begins in childhood. Atopic dermatitis cannot be spread from person to person. No one knows what causes atopic dermatitis. Depending on

Arthritis

https://www.niams.nih.gov/health-topics/arthritis

What is arthritis? "Arthritis" literally means joint inflammation. Although joint inflammation is a symptom or sign rather than a specific diagnosis, the term arthritis is often used to refer to any disorder that affects the joints. Joints are places where two bones meet, such as your elbow or knee. There are different types of arthritis. In some diseases in which arthritis occurs, other organs, such as your eyes, heart, or skin, can also be affected. Fortunately, current treatments allow most people with arthritis to lead active and productive lives.

Raynaud’s Phenomenon

https://www.niams.nih.gov/health-topics/raynauds-phenomenon

What is Raynaud’s phenomenon? Raynaud’s phenomenon is a condition that causes the blood vessels in the hands and feet to narrow, decreasing blood flow. When this happens, parts of the body—usually the fingers and toes—become cold and numb, and change color (usually, to white or blue). An attack usually happens from exposure to cold or stress.

Fenómeno de Raynaud

https://www.niams.nih.gov/health-topics/raynauds-phenomenon

¿Qué es el fenómeno de Raynaud? El fenómeno de Raynaud es un trastorno que hace que los vasos sanguíneos de las manos y los pies se vuelvan más angostos, disminuyendo así el flujo sanguíneo. Cuando esto sucede, partes del cuerpo, usualmente los dedos de las manos y los pies, se enfrían y se adormecen, y cambian de color (por lo general, se ponen blancos o azules). A menudo, un ataque o episodio de estos ocurre por exposición al frío o por estrés.

The Effect of Atorvastatin on Microvascular Endothelial Function and Raynaud in Early Diffuse Systemic Sclerosis

https://www.niams.nih.gov/grants-funding/clinical-trials-spotlight/effect-atorvastatin-microvascular-endothelial-function-and

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) supports a range of clinical trials studying new and existing interventions for prevention and treatment of arthritis, musculoskeletal, and skin diseases. Recruitment for this clinical trial complete. Updates will be made to this page when the study completes data

What Is NIAMS?

https://www.niams.nih.gov/about/what-is-niams

The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) is one of 27 Institutes and Centers at the National Institutes of Health (NIH), the nation’s premier biomedical research agency. Established in 1986, the NIAMS supports research into the causes, treatment, and prevention of arthritis and musculoskeletal and skin diseases; the training of basic and clinical scientists to carry out this research; and the dissemination of information on research progress in these diseases.

Honoring Health — What Your Community Needs To Know About COVID-19 — April 2020

https://www.niams.nih.gov/newsletters/aian-newsletter/2020/aian-newsletter-april-2020

p.no-pdf a.pdf:before { content: ''; } @media only screen and (min-width: 601px) { img.align-right { width: 22% !important; } } .photo.right { display: none; } hr { clear: both; border-right: medium none; border-top: 1px solid rgba(0,0,0,.1); border-left: medium none; border-bottom: medium none; height: 1px; } What Your Community Needs To Know About COVID-19 The coronavirus disease 2019 (COVID-19) pandemic is an emerging, rapidly evolving situation. For this reason, we are focusing this issue of Honoring Health on the latest public health and research information available, to help you keep your community informed. Featured Health Information Latest Public Health Information From

What Others are Saying About the Accelerating Medicines Partnership’s Rheumatoid Arthritis and Lupus Network Awards

https://www.niams.nih.gov/grants-funding/funded-research/accelerating-medicines/what-others-are-saying

NIAMS updated this page February 13, 2017, due to organization name changes. What Others are Saying About the Accelerating Medicines Partnership’s Rheumatoid Arthritis and Lupus Network Awards AbbVie: "AbbVie is proud to support the AMP RA/Lupus Network and collaborate on emerging research to improve the treatment options for patients living

Systemic Lupus Erythematosus (Lupus)

https://www.niams.nih.gov/health-topics/lupus

What is systemic lupus erythematosus (lupus)? Systemic lupus erythematosus (lupus) is a chronic (long-lasting) autoimmune disease that can affect many parts of the body, including the: Skin. Joints. Heart. Lungs. Kidneys. Brain. Lupus happens when the immune system, which normally helps protect the body from infection and disease, attacks its own tissues. This attack causes inflammation and, in some cases, permanent tissue damage. If you have lupus, you may have times of illness (flares) and times of wellness (remission). Lupus flares can be mild to serious, and they do not follow a pattern. However, with treatment, many people with lupus

Roundtable on Scleroderma: Advancing Potential Drugs to Patient Care

https://www.niams.nih.gov/about/meetings-events/roundtables/roundtable-scleroderma-advancing-potential-drugs-patient-care

Roundtable on Scleroderma: Advancing Potential Drugs to Patient Care February 27, 2015 Background Scleroderma is a complex disease resulting from inflammation and soft tissue fibrosis (hardening). The organ and tissue systems affected by the disease include skin, blood vessels, gastrointestinal tract, lung, heart, kidney, muscles, and joints. Scleroderma is considered an autoimmune disease, in which much of the tissue damage is thought to be caused by the patient’s own immune system. Clinically, this progressive disease is challenging to treat or prevent since there is no proven, approved therapy to alter the underlying cause. Fibrosis results in high morbidity for patients

Roundtable on Scleroderma: Advancing Potential Drugs to Patient Care

https://www.niams.nih.gov/newsroom/meetings-events/roundtables/scleroderma-advancing-potential-drugs-to-patient-care

Background Scleroderma is a complex disease resulting from inflammation and soft tissue fibrosis (hardening). The organ and tissue systems affected by the disease include skin, blood vessels, gastrointestinal tract, lung, heart, kidney, muscles, and joints. Scleroderma is considered an autoimmune disease, in which much of the tissue damage is thought to be caused by the patient’s own immune system. Clinically, this progressive disease is challenging to treat or prevent since there is no proven, approved therapy to alter the underlying cause. Fibrosis results in high morbidity for patients with substantial impact on their quality of life, as well as high

Clinical Trials in the Spotlight - Completed Recruitment

https://www.niams.nih.gov/grants-funding/clinical-trials-spotlight/clinical-trials-spotlight-completed-recruitment

Studies That Have Completed Recruitment Trials that are no longer recruiting but remain active to complete other study activities are found here. Click on a disease/condition below to learn more about a range of clinical trials studying new and existing interventions for prevention and treatment of arthritis, musculoskeletal and skin